KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) Revenue (2016 - 2026)

Edwards Lifesciences has reported Revenue over the past 17 years, most recently at $1.6 billion for Q4 2025.

  • For Q4 2025, Revenue rose 13.26% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $6.1 billion, up 11.55%, while the annual FY2025 figure was $6.1 billion, 11.55% up from the prior year.
  • Revenue for Q4 2025 was $1.6 billion at Edwards Lifesciences, up from $1.6 billion in the prior quarter.
  • Over five years, Revenue peaked at $1.6 billion in Q4 2025 and troughed at $429.9 million in Q4 2022.
  • A 5-year average of $1.3 billion and a median of $1.3 billion in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: tumbled 67.67% in 2022 and later skyrocketed 194.58% in 2023.
  • Year by year, Revenue stood at $1.3 billion in 2021, then tumbled by 67.67% to $429.9 million in 2022, then skyrocketed by 194.58% to $1.3 billion in 2023, then increased by 9.43% to $1.4 billion in 2024, then rose by 13.26% to $1.6 billion in 2025.
  • Business Quant data shows Revenue for EW at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.